<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">JAMA Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">JAMA Oncol</journal-id>
<journal-id journal-id-type="pmc">JAMA Oncol</journal-id>
<journal-title-group>
<journal-title>JAMA Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">2374-2437</issn>
<issn pub-type="epub">2374-2445</issn>
<publisher>
<publisher-name>American Medical Association</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30128536</article-id>
<article-id pub-id-type="pmc">6439764</article-id>
<article-id pub-id-type="doi">10.1001/jamaoncol.2018.2956</article-id>
<article-id pub-id-type="publisher-id">coi180058</article-id>
<article-categories>
<subj-group specific-use="electronic" subj-group-type="category">
<subject>Research</subject>
</subj-group>
<subj-group specific-use="print" subj-group-type="domain">
<subject>Research</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Investigation</subject>
</subj-group>
<subj-group specific-use="electronic" subj-group-type="featured">
<subject>Featured</subject>
</subj-group>
<subj-group subj-group-type="online-first">
<subject>Online First</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Association of Breast and Ovarian Cancers With Predisposition Genes
Identified by Large-Scale Sequencing</article-title>
<alt-title alt-title-type="headline">Association of Breast and Ovarian Cancers With
Predisposition Genes Identified by Large-Scale Sequencing</alt-title>
<alt-title alt-title-type="running-head">Association of Breast and Ovarian Cancers With
Predisposition Genes Identified by Large-Scale Sequencing</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Hsiao-Mei</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Shuwei</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Black</surname>
<given-names>Mary Helen</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Shela</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="coi180058aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hoiness</surname>
<given-names>Robert</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Sitao</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mu</surname>
<given-names>Wenbo</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huether</surname>
<given-names>Robert</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="coi180058aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Jefferey</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sridhar</surname>
<given-names>Srijani</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="coi180058aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tian</surname>
<given-names>Yuan</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McFarland</surname>
<given-names>Rachel</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="coi180058aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dolinsky</surname>
<given-names>Jill</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tippin Davis</surname>
<given-names>Brigette</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mexal</surname>
<given-names>Sharon</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dunlop</surname>
<given-names>Charles</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elliott</surname>
<given-names>Aaron</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180058aff1">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="coi180058aff1"><label>1</label>Ambry Genetics, Aliso Viejo, California</aff>
<aff id="coi180058aff2"><label>2</label>Now with Simcere Pharmaceutical, Jiangsu, China</aff>
<aff id="coi180058aff3"><label>3</label>Tempus, Chicago, Illinois</aff>
<aff id="coi180058aff4"><label>4</label>Intellia Therapeutics, Cambridge, Massachusetts</aff>
<aff id="coi180058aff5"><label>5</label>Department of Epidemiology, School of Medicine,
University of California, Irvine</aff>
<author-notes>
<title>Article Information</title>
<p><bold>Accepted for Publication:</bold> May 4, 2018.</p>
<p content-type="published-online"><bold>Published Online:</bold> August 16, 2018.
doi:<uri content-type="doi">10.1001/jamaoncol.2018.2956</uri></p>
<p content-type="correction-note"><bold>Correction:</bold> This article was corrected on
January 10, 2019, to update the text regarding the <italic>MSH6</italic> c.2945delC
variant in the Discussion section, and to update data for BC subtypes in patients with BC
in Table 1.</p>
<corresp id="coi180058cor1"><bold>Corresponding Author:</bold> Shuwei Li, PhD, Ambry
Genetics, 15 Argonaut, Aliso Viejo, CA 92656 (<email xlink:href="sli@ambrygen.com">sli@ambrygen.com</email>).</corresp>
<p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Lu and Li
contributed equally and are considered co–first authors. Drs Lu and Li had full
access to all the data in the study and take responsibility for the integrity of the data
and the accuracy of the data analysis.</p>
<p><italic>Concept and design:</italic> Lu, Black, Lee, Hoiness, Chen, Tippin Davis, Mexal,
Dunlop, Elliott.</p>
<p><italic>Acquisition, analysis, or interpretation of data:</italic> Lu, Li, Black, Lee,
Hoiness, Wu, Mu, Huether, Chen, Sridhar, Tian, McFarland, Dolinsky, Mexal.</p>
<p><italic>Drafting of the manuscript:</italic> Li, Black, Lee, Hoiness, Mu, Huether, Chen,
Mexal.</p>
<p><italic>Critical revision of the manuscript for important intellectual content:</italic>
Lu, Li, Black, Lee, Wu, Mu, Huether, Sridhar, Tian, McFarland, Dolinsky, Tippin Davis,
Dunlop, Elliott.</p>
<p><italic>Statistical analysis:</italic> Lu, Li, Black, Mu, Tian.</p>
<p><italic>Administrative, technical, or material support:</italic> Lu, Lee, Hoiness, Wu,
Chen, Sridhar, McFarland, Tippin Davis, Mexal, Dunlop, Elliott.</p>
<p><italic>Supervision:</italic> Lu, Black, Lee, Tippin Davis, Dunlop, Elliott.</p>
<p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> All authors
were employed by and received a salary from Ambry Genetics Inc at the time of the
study.</p>
<p content-type="funding-statement"><bold>Funding/Support:</bold> The study was sponsored by
<funding-source rid="sp1">Ambry Genetics Inc</funding-source>.</p>
<p><bold>Role of Funder/Sponsor:</bold> The sponsor provided funding for the study by
setting aside funds to be used exclusively for research, distinct from clinical
operations, and via employee authors, the sponsor provided input into the study design.
The funder had no role in the conduct of the study; collection, management, analysis, and
interpretation of the data; preparation, review, or approval of the manuscript; or the
decision to submit the manuscript for publication.</p>
<p><bold>Additional Contributions:</bold> We thank the patients, their families, and their
physicians and genetic counselors for participating and for providing samples and clinical
histories.</p>
</author-notes>
<pub-date iso-8601-date="2018-08-16T10:00" pub-type="epub">
<day>16</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ecorrected">
<day>10</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>16</day>
<month>8</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
<volume>5</volume>
<issue>1</issue>
<fpage>51</fpage>
<lpage>57</lpage>
<history>
<date date-type="received">
<day>21</day>
<month>12</month>
<year>2017</year>
</date>
<date date-type="final">
<day>2</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>4</day>
<month>5</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright 2018 American Medical Association. All Rights
Reserved.</copyright-statement>
</permissions>
<self-uri content-type="pdf-version" xlink:href="jamaoncol-5-51.pdf">jamaoncol-5-51.pdf</self-uri>
<self-uri content-type="roundpoint" xlink:href="https://app.jamanetwork.com/?doi=10.1001/jamaoncol.2018.2956"></self-uri>
<self-uri content-type="silverchair" xlink:href="https://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.2956"></self-uri>
<related-article ext-link-type="doi" id="d35e403" related-article-type="commentary" xlink:href="10.1001/jamaoncol.2018.3034"></related-article>
<related-article ext-link-type="doi" id="d35e404" related-article-type="letter" specific-use="electronic" xlink:href="10.1001/jamaoncol.2018.6905"></related-article>
<related-article ext-link-type="doi" id="d35e405" related-article-type="letter" specific-use="electronic" xlink:href="10.1001/jamaoncol.2018.6908"></related-article>
<related-article ext-link-type="doi" id="d35e406" related-article-type="letter" specific-use="electronic" xlink:href="10.1001/jamaoncol.2018.6911"></related-article>
<related-article ext-link-type="doi" id="d35e407" related-article-type="letter" specific-use="electronic" xlink:href="10.1001/jamaoncol.2018.6914"></related-article>
<related-article ext-link-type="doi" id="d35e408" related-article-type="correction-forward" xlink:href="10.1001/jamaoncol.2018.6918"></related-article>
<abstract abstract-type="teaser">
<p>This study of patients with breast cancer, ovarian cancer, or both compared with controls
uses whole-exome sequencing to investigate whether non-<italic>BRCA</italic> genes are
associated with an increased risk of those cancers.</p>
</abstract>
<abstract abstract-type="key-points">
<title>Key Points</title>
<sec id="ab-coi180058-1">
<title>Question</title>
<p>Which non-<italic>BRCA</italic> genes are associated with breast or ovarian cancer and
what are the magnitudes of those risks?</p>
</sec>
<sec id="ab-coi180058-2">
<title>Findings</title>
<p>In this study assessing whole-exome sequencing results from 11 416 patients with
breast cancer, ovarian cancer, or both and 3988 controls, an increased risk of breast
cancer was associated with <italic>PALB2, ATM, CHEK2,</italic> and <italic>MSH6</italic>
genes, whereas <italic>MSH6, RAD51C</italic>, <italic>TP53</italic>, and
<italic>ATM</italic> genes were associated with an increased risk of ovarian
cancer.</p>
</sec>
<sec id="ab-coi180058-3">
<title>Meaning</title>
<p>In addition to confirming several well-known breast or ovarian cancer gene
associations, this study identified <italic>MSH6</italic> and <italic>ATM</italic> as
possible moderate-risk breast and ovarian cancer predisposition genes, respectively.</p>
</sec>
</abstract>
<abstract>
<sec id="ab-coi180058-4">
<title>Importance</title>
<p>Since the discovery of <italic>BRCA1</italic> and <italic>BRCA2</italic>, multiple
high- and moderate-penetrance genes have been reported as risk factors for hereditary
breast cancer, ovarian cancer, or both; however, it is unclear whether these findings
represent the complete genetic landscape of these cancers. Systematic investigation of
the genetic contributions to breast and ovarian cancers is needed to confirm these
findings and explore potentially new associations.</p>
</sec>
<sec id="ab-coi180058-5">
<title>Objective</title>
<p>To confirm reported and identify additional predisposition genes for breast or ovarian
cancer.</p>
</sec>
<sec id="ab-coi180058-6">
<title>Design, Setting, and Participants</title>
<p>In this sample of 11 416 patients with clinical features of breast cancer,
ovarian cancer, or both who were referred for genetic testing from 1200 hospitals and
clinics across the United States and of 3988 controls who were referred for genetic
testing for noncancer conditions between 2014 and 2015, whole-exome sequencing was
conducted and gene-phenotype associations were examined. Case-control analyses using the
Genome Aggregation Database as a set of reference controls were also conducted.</p>
</sec>
<sec id="ab-coi180058-7">
<title>Main Outcomes and Measures</title>
<p>Breast cancer risk associated with pathogenic variants among 625 cancer predisposition
genes; association of identified predisposition breast or ovarian cancer genes with the
breast cancer subtypes invasive ductal, invasive lobular, hormone
receptor–positive, hormone receptor–negative, and male, and with early-onset
disease.</p>
</sec>
<sec id="ab-coi180058-8">
<title>Results</title>
<p>Of 9639 patients with breast cancer, 3960 (41.1%) were early-onset cases (≤45
years at diagnosis) and 123 (1.3%) were male, with men having an older age at diagnosis
than women (mean [SD] age, 61.8 [12.8] vs 48.6 [11.4] years). Of 2051 women with ovarian
cancer, 445 (21.7%) received a diagnosis at 45 years or younger. Enrichment of
pathogenic variants were identified in 4 non-<italic>BRCA</italic> genes associated with
breast cancer risk: <italic>ATM</italic> (odds ratio [OR], 2.97; 95% CI, 1.67-5.68),
<italic>CHEK2</italic> (OR, 2.19; 95% CI, 1.40-3.56), <italic>PALB2</italic> (OR,
5.53; 95% CI, 2.24-17.65), and <italic>MSH6</italic> (OR, 2.59; 95% CI, 1.35-5.44).
Increased risk for ovarian cancer was associated with 4 genes: <italic>MSH6</italic>
(OR, 4.16; 95% CI, 1.95-9.47), <italic>RAD51C</italic> (OR, not estimable;
false-discovery rate–corrected <italic>P</italic> = .004),
<italic>TP53</italic> (OR, 18.50; 95% CI, 2.56-808.10), and <italic>ATM</italic> (OR,
2.85; 95% CI, 1.30-6.32). Neither the MRN complex genes nor <italic>CDKN2A</italic> was
associated with increased breast or ovarian cancer risk. The findings also do not
support previously reported breast cancer associations with the ovarian cancer
susceptibility genes <italic>BRIP1</italic>, <italic>RAD51C</italic>, and
<italic>RAD51D,</italic> or mismatch repair genes <italic>MSH2</italic> and
<italic>PMS2</italic>.</p>
</sec>
<sec id="ab-coi180058-9">
<title>Conclusions and Relevance</title>
<p>The results of this large-scale exome sequencing of patients and controls shed light on
both well-established and controversial non-<italic>BRCA</italic> predisposition gene
associations with breast or ovarian cancer reported to date and may implicate additional
breast or ovarian cancer susceptibility gene candidates involved in DNA repair and
genomic maintenance.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source id="sp1">Ambry Genetics Inc</funding-source>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>